Eyenovia, Inc.’s Post

Breaking News in Vision Technology! Keratoconus Follow -up! After the successful on-eye demonstration of our revolutionary technology ALMA Smart Lens, let’s focus on patients suffering from Keratoconus and how Smart Contact Lens could help them in the near future to manage their Irregular Astigmatism. This innovative smart lens promises a non-surgical breakthrough for patients battling vision disorders. At Azalea Vision, we are dedicated to revolutionizing eye care through our smart contact lens technology. By addressing diverse visual challenges, from keratoconus to presbyopia and photophobia, we commit to provide adaptive, effective, and accessible solutions for a brighter, clearer tomorrow. Stay tuned for more updates on this game-changing solution! Learn more about ALMA at: https://lnkd.in/ecfrQ4-c #AzaleaVision #ALMA #VisionTechnology #Innovation #Ophthalmology #HealthcareRevolution #smartcontactlens #medtech  #investors #healthtech #startup #eyecare #optometry #InnovationInEyeCare #EyeHealth #VisionLoss #healthcareinnovation #medicaldevices #venturecapital #Optometry #EyeDisease #LASIK #EyeSurgery #Ophthalmologist

Injuries of the rotator cuff result in a growing demand for surgical interventions … ➡️ Swipe through to discover more about the rotator cuff and the current clinical issue! #Startup #ZuriMED #MedTech #RotatorCuffTear #SurgicalDemand

Steps for boosting revenue of Eye clinics worldwide ,are  not so hard to embark on ………….                                                 Using the most of your permit or license or qualification is one of the best ways to raise your revenue. Considering a holistic approach would enable in better patient outcome and aid in patient retention. However, a challenge to offer holistic eye care is the requirement of multiple devices which in turn requires heavy investments and overhead expenses, so as an optimal solution best is to invest in devices offering multiple diagnostic capacities that also take care of security and convenience of patient data handling. What are your thoughts on this? Hashtags: #eyeexam, #eyecare, #eyeimaging, #Vlenzor, #VlenzorTechnologies,#medicaltechnology #ophthalmology #optometry #startup #venturecapital #investment . 

Excited to be closing out the year with 2 further exit announcements! It's no secret that 2023, with its unforgiving macroeconomic and funding environment, has been rough for the startup industry. Nevertheless, I continue to be impressed by all the entrepreneurs who are still relentlessly building and innovating each day. I remain optimistic that 2024 will bring new opportunities in many industries, with many chances for me to reflect on my own development and future. PathologyWatch was acquired by Australia's own Sonic Healthcare for $150M. The company is a leader in using AI to provide digital solutions in dermatology pathology. Spectrum Labs (An ActiveFence Company), last valued at $137M is focusing on rooting out and moderating toxic online behaviours across languages, making the internet safer one comment at a time. #startups #innovation #newbeginnings #venturecapital #angelinvesting https://lnkd.in/gzYQN2e3 https://lnkd.in/gtj8n8EP

#Lenoss Medical Secures Investment from #XcellerantVentures.The deal’s total value was not made public. With the funding, the business hopes to #further the #development and #commercialization of #OsteoPearl, a #biological option for treating #osteoporotic vertebral compression fractures that #doctors can prescribe. Lenoss, under the #leadership of CEO Dom Messerli, is developing the OsteoPearl VBA System, that utilises #minimally invasive, cement-free technology along with #healthy bone’s #inherent healing abilities to provide a wholly biologic solution for #stabilising #spinal #fractures. Lenoss Medical, In #vertebral body #augmentation, a surgical tool is inserted into a broken #vertebral body caused by #osteoporosis or trauma. A device is inserted to fill the #hollow and #stabilise the #fractured vertebrae once the cavity has been #formed. Lenoss Medical Xcellerant Ventures Dom Messerli, MBA #lenossmedical #funding #startup

My first podcast! I had so much fun with Kyle Kruse 🚀 and Richard Meiklejohn talking about Imricor and how we are advancing medicine with our technology. Thanks guys for the invitation! The link is below if you are interested in learning about what we are doing.

Ever wondered how a bold idea can turn into a multimillion-dollar success in the medtech industry? Let me tell you about a startup (and our client) that did just that. This startup had a wild dream to revolutionize orthopedic implants. They had a design that fixed all the annoying issues with existing implants, but they needed serious cash to get things rolling and clear the regulatory hurdles. 🔹 Snagging a $500,000 grant from the NIH was like finding a golden ticket. This cash injection helped them prove their concept was more than just a pretty sketch. 🔹 With proof in hand, they caught the eye of a venture capitalist who threw in another $1.5 million. 🔹 Armed with $2 million, they built a prototype. The pre-clinical trials showed it was better than the old-school implants, attracting even more investors and partners. 🔹 Fast forward two years, and they got FDA approval and a big-time manufacturer bought them out. From a wild idea to a market sensation, this startup’s journey is proof that with the right plan and a bit of luck, anything’s possible in the medtech world. #Innovation #OrthopedicImplants #StartupSuccess #MedicalDevices #FundingStrategy #FDAApproval #MedTech #Entrepreneurship

ViaLase, Inc. , A clinical-stage #medical technology startup called has raised $40 million in a series C round of funding with the goal of filling gaps in the current paradigm for treating glaucoma. The financing was spearheaded by a new investor, with backing from existing investors such as Arboretum Ventures, Venture Investors, Health Fund, and Falcon Vision, an ophthalmology investment platform backed by KKR. The company, led by its founder and CEO, Tibor Juhasz, PhD, plans to use the money to make sure that the ViaLase® Laser* continues to advance clinically, legally, and #commercially. The first femtosecond laser used to treat primary open angle glaucoma (POAG) will be the ViaLase Laser, if approved. The ViaLuxeTM Laser System is intended to lower intraocular pressure (IOP) by non-invasively creating customised drainage channels via the #trabecular meshwork combining #femtosecond laser accuracy and micron-accurate gonio imaging. ViaLase, Inc Hadi Srass Ferenc Raksi Carlos Suarez Read more - https://lnkd.in/gBqtkjnF To share your startup story write us on - contact@startuprise.io #ViaLase #medicalstartup #medical #technology #glaucoma #commercially #accuracy #startup #startupnews #fundingnews #news

#fundingalert 💼Company: Atraverse Medical, Inc. 💰Funding: $12.5Million ⚡Round: Seed 👥Investors: Physicians, reputable venture investors, and successful medtech entrepreneurs. Atraverse Medical is a medical device company pioneering next-generation left-heart access technology. The company’s proprietary HOTWIRE™ system, featuring universal sheath compatibility and optimized RF technology, aims to enhance outcomes and streamline workflows for physicians treating cardiovascular disease in millions of patients worldwide. The money will be used by the firm to further its early commercialization plans and increase its R&D activities. Atraverse Medical, led by CEO John Slump, announced that its HOTWIRETM radiofrequency (RF) guidewire has received FDA clearance. Steven Mickelsen , John Slump Read more - https://lnkd.in/gMNTAzFV To share your startup story write us on - contact@startuprise.io #AtraverseMedical #medicaldevicecompany #radiofrequency #commercialization #technology #funding #fundingnews #startup #startupnews #startuprise

Last week, i completed my second angel investment in #Israel via my investment firm Four Pursuits Ventures. ALTHEA MEDICAL LTD. is a medical devices startup developing a non-surgical treatment for patients suffering from Pulmonary Embolism (PE). PE is a blockage or clot in one of the pulmonary arteries leading to the lung that can result in death in up to one-third of all patients. Current treatment options include administration of blood thinners that carries high risk of intracranial bleeding, and surgical pulmonary embolectomy, which is a highly invasive procedure. Minimally invasive catheter-based interventions are fast becoming the preferred approach, as they allow the physician to quickly navigate to the blocked area and relieve clot burden, thereby achieving hemodynamic stability. Althea's product enables: -- easy navigation to target site without stenting of the heart -- mechanical removal system to assist in removal of challenging clots Happy to be part of your team Lia Ofek, Rafi Benary. Peregrine Ventures #istandwithisrael #investment